trans-Cyanocombretastatin A-4 (trans-CA-4) analogues have been structurally modified to afford their more stable CA-4-(2H)-1,2,3-triazole analogues. Fifteen novel, stable 4-heteroaryl-5-aryl-(2H)-1,2,3-triazole CA-4 analogues (8a-i, 9 and 11a-e) were evaluated for anti-cancer activity against a panel of 60 human cancer cell lines. These analogues displayed potent cytotoxic activity against both hematological and solid tumor cell lines with GI 50 values in the low nanomolar range. The most potent compound, 8a, was a 10 benzothiophen-2-yl analogue that incorporated a 3,4,5-trimethoxyphenyl moiety connected to the (2H)-1,2,3-triazole ring system. Compound 8a exhibited GI 50 values of <10 nM against 80% of the cancer cell lines in panel. Three triazole analogues, 8a, 8b and 8g, showed particularly potent growth inhibition against the triple negative Hs578T breast cancer cell line with GI 50 values of 10.3 nM, 66.5 nM and 20.3 nM, respectively. Molecular docking studies suggest that these compounds bind to the same hydrophobic pocket at the interface of α-and β-tubulin that is occupied by colchicine and cis-CA-4, and are stabilized by Van der Waals' interactions with 15 surrounding amino acid residues. Compound 8a was found to inhibit tubulin polymerization in vitro with an IC 50 value of 1.7 µM. The potent cytotoxicity of these novel compounds and their inhibition of tubulin dynamics make these triazole analogues promising candidates for development as anti-cancer drugs.
Introduction
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The combretastatins (Fig. 1, 1 and 2) were first isolated from the South African bush willow tree Combretum caffrum, of which cis-combretastatin A-4 (cis-CA-4, 1) is the major component. 1 Three analogues of combretastatin cis-CA-4: CA-4P (3), Oxi4503 (4) and AVE8062 (5) (Fig. 1 ) are currently in 25 clinical trials for treatment of a variety of cancers, and have improved water solubility, cytotoxicity, efficacy and a better safety profile compared to cis-CA-4. [2] [3] [4] [5] These combretastatin analogues are also known to be vascular disrupting agents (VDAs) and have proven to be advantageous cytotoxic agents, 30 since they target the tumor vasculature causing hemorrhagic necrosis and cell death. 6 The CA-4 analogues are generally classified as tubulin polymerization inhibitors with an anti-mitotic mechanism of 35 action, due to their ability to disrupt microtubule dynamics and hence mitotic spindle formation by binding to the same site as colchicine on tubulin dimers. 7, 8 These small molecule VDAs also induce hypoxia-driven necrosis of solid tumors, and are able to induce apoptosis by cell-cycle arrest.
Fig 1. Chemical structures of cis-CA-4 (1) and its derivatives (2-6).
CA-4 analogues are highly cytotoxic against human cancer cell lines. CA4-P (3) exhibits potent cytotoxicity against 70 anaplastic thyroid cancer cells lines, 11 and Oxi-4503 (4) is a potent anti-leukemic compound.
12 AVE8062 (5) is an effective cytotoxic agent against head and neck squamous cell carcinoma, 13 including multidrug resistant forms of this cell line. 14 Tron et al. have reported that the cis-configured double 75 bond of cis-CA-4, with a 3,4,5-trimethoxyphenyl ring (Ring A) on one side and a 4-methoxysubstituted phenyl ring on the other side (Ring B), is an essential structural moiety for optimal cytotoxic activity in cis-CA-4 analogues. [15] [16] [17] Recently, we have investigated the anticancer activities of a series of transcyano-CA-4 analogs in which replacement of ring B with different heterocycles, such as quinoline (6) , benzothiophene 5 (7a-f and 10a-c), benzofuran (7g-h) and indole (7i and 10d-e), has occurred; we have determined the effect of these structural changes on anticancer activity. 18, 19 We have also evaluated the effects of structurally modifying ring A by introducing differently substituted methoxy and hydroxy moieties into this 10 phenyl ring. 18 The isomerization of the cis-configured CA-4 analogues to their trans-forms in solution is one of the major disadvantages of these molecules. In this respect, we have shown that 15 isomerization of trans-cyano CA-4 analogues to their cis-cyano CA-4 forms is also observed in solution. 18 To restrict cis-trans isomerization in these CA-4 analogues, different heterocylic ring systems, such as doxolane, 20 been incorporated into the stilbene double bond.
In the present report, we have prepared a series of stable analogues of cis-cyano CA-4 by constructing a triazole ring system across the olefinic bond between aromatic rings A and 25 B. This (2H)-1,2,3-triazole heterocyclic bridge unit was established by chemical modification of existing trans-cyano CA-4 analogues via [3+2] cycloaddition of azide ion across the double bond. This novel and simple structural modification led to an improvement in the stability and biological properties of 30 these new CA-4 analogues. We now report on the synthesis and in vitro anti-cancer activities of a variety of 4-heteroaryl-5-aryl-(2H)-1,2,3-triazole CA-4 analogues, and their ability to inhibit tubulin polymerization in vitro. Some of the analogues were also tested for cytotoxicity against Hs578T breast cancer cell 35 lines. In addition, molecular modeling studies of the most active inhibitors indicate that they interact with the colchicine binding site on α,β-tubulin, and this has been confirmed in in vitro tubulin polymerization inhibition studies. 40 
Chemistry
The formation of the 1,2,3-triazole ring system is well known in the literature as a "click chemistry" product from a thermally induced Cu(I)-catalyzed (CuAAC) Huisgen 45 [3+2]cycloaddition azide-alkyne reaction. 30 The click chemistry approach is widely used in the synthesis and regioisomeric formation of 1,4-disubstituted-1,2,3-triazoles in the presence of CuAAC in excellent yields. [31] [32] [33] [34] The regioisomeric synthesis of 1,5-disubstituted-1,2,3-triazoles has 50 also been reported with high selectivity utilizing different metal ions in magnesium-, cerium-and ruthenium-mediated reactions. [35] [36] [37] We have recently reported the synthesis of a wide variety of 55 4,5-disubstitued-1,2,3-(1H)-triazole analogues.
38, 39 We used a two stage synthesis, i.e. the preparation of the precursor transcyano-CA-4 analogue, which utilizes our previously published procedure, 18 followed by synthesis of the target (2H)-1,2,3-triazole CA-4 compounds 8a-8i and 11a-11e by reaction of the 60 trans-cyano CA-4 analogue with sodium azide in DMSO at 100 o C over 1-6 hrs utilizing L-proline as a Lewis base. The desired (2H)-1,2,3-triazole products were obtained in 75-96% yield 38 (Schemes 1 and 2) (Note: the use of cis-cyano CA-4 analogues in the above reaction led to lower yields of the 65 triazole product 39 ). The N-2 methylated analogue 9 was prepared from the reaction of 8a with methyl iodide/K 2 CO 3 in acetone (Scheme 2). Confirmation of the structure and purity of these analogues is reported elsewhere, and was obtained from single crystal X-ray diffraction studies, 40 and 1 H-NMR, 13 C-
70
NMR and high resolution mass spectroscopic analysis. 
Biological Evaluation
A. In vitro growth inhibition and cytotoxicity
The above triazole analogues were evaluated for their anticancer activities against a panel of 60 human cancer cell 5 lines, which incorporates different subpanels representing leukemia, non-small cell lung, colon, central nervous system, melanoma, ovary, renal, prostate, and breast cancer cell lines, at a concentration of 10 -5 M utilizing the procedure described by Rubinstein et al. 41 Compounds that showed 60% growth 10 inhibition in at least eight of the 60 cell lines screened were further evaluated in a five-dose screen.
From the preliminary screen, compounds 8a, 11b, 11d, 11e and 9 were selected for five-dose studies and their GI 50 values 15 determined ( Table 1) . GI 50 values represent the molar drug concentration required to cause 50% growth inhibition. In the five-dose studies, 5 different concentrations at 10-fold dilutions (10 -4 M, 10 -5 M, 10 -6 M, 10 -7 M and 10 -8 M) were utilized and incubations were carried out over 48 h exposure to drug. 20 Compounds 8a, 11b, 11d, 11e and 9 exhibited GI 50 values in the low nanomolar range against all 60 human cancer cell lines in the panel. The results are presented in Table 1 . Compound 8a and its analogues (8b and 8g) were tested for cytotoxicity against the triple negative breast cancer (TNBC)-derived Hs578T cell line. The GI 50 estimates for compounds 20 8a, 8b, and 8g were all below 100 nM (Fig. 2) . However, the potency of compound 8a remained two-to six-fold greater than either 8b or 8g. Comparing the results for 8a, 8b and 8g revealed that replacing the 3,4,5-trimethoxyphenyl moiety of 8a with a 3,5-dimethoxyphenyl group to afford 8b, results in a 25 more pronounced effect on cytotoxicity than replacing the benzothiophen-2-yl moiety with a benzofuran-2-yl group (8g). Fitting the data to a variable slope log (inhibitor) vs. response equation yields the following GI 50 estimates (with 95% confidence intervals): 8a: GI 50 = 10 (9.8-11) nM, 8b: GI 50 = 65 (52-82) nM, 8g: GI 50 = 20 (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) nM.
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C. Molecular modeling studies
Molecular modeling studies were performed for four active (2H)-1,2,3-triazoles analogues (8a, 8g, 11d, and 11e) using SYBYL-X 2.1. Binding interactions of these triazole analogues 55 were studied by docking them at the colchicine-binding site on tubulin. 3-D coordinates for the tubulin-colchicine complex were obtained from the RSCB protein data bank (pdb id: 4O2B). For preparation of tubulin to perform the docking calculations, the geometry of the protein molecule was 60 optimized using energy minimization techniques after the addition of hydrogen atoms. Since no structured water molecule was present in the binding pocket, all the water molecules in the protein were deleted during the preparation of structure for docking calculations. Amino acid side chain 65 bumps were fixed and terminal amino acid were charged to mimic the biological environment. Hydrogen atoms were added to the structure. The Kollman force field was applied and the protein was minimized using the Powell method and Pullman charges. The triazole analogue structures were initially 70 generated in 2-D format in Chem-Draw. For generating energyminimized structures, the 2-D structures were converted to 3-D using ChemDraw3D and all the structures were saved in Mol2 format. The structures were imported to Sybyl in the Mol2 format. In SYBYL, TRIPOS force field was applied and 3-D 75 structure coordinates were taken through a series of minimization processes. Firstly, all the structures we minimized using the BFGS method. Then, MOPAC charges were calculated for each molecule followed by another minimization step. Each molecule was then checked for 80 charges, bond angle, torsion angles and geometry. All the molecules were saved in one directory and prepared for docking via the ligand preparation tool. For the docking analysis using the Surflex program, a protomol was generated at the colchicine-binding site in tubulin. This protomol is the with THR 356, and 11e makes hydrogen bond with ALA 317 (Fig. 3) . ASN 258 hydrogen bond interactions are common in all four docked triazoles. In summary, 8a exhibited the strongest binding interactions with tubulin at the colchicine-binding site, which is consistent with the anticancer screening data (Table 1) . Thus, the above molecular modeling data predicts that stable, more drug-like 30 triazolo derivatives of the cis-cyano CA-4 analogues formed by constructing a heterocyclic ring system across the olefinic bond between aromatic rings A and B will retain the tubulin targeting properties of the parent compounds.
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D. Inhibition of tubulin polymerization
The ability of compounds 8a, 11d, 11e and 9 to inhibit tubulin polymerization was determined using a commercially available in vitro assay (Cytoskeleton Inc., Denver, CO). We 40 examined the ability of three of the most active CA-4-(2H)-1,2,3-triazoles, 8a, 11d, and 11e, to inhibit tubulin polymerization using an in vitro assay. Compound 8a, which exhibited the greatest overall potency against the NCI 60 human cancer cell line panel, was found to inhibit tubulin 45 polymerization with an IC 50 value of 1.7 (± 0.4) µM (Fig. 4) , where the reported values represent the mean ± s.d. (n=3). Compounds 11d and 11e inhibited tubulin polymerization with IC 50 values of 18.5 (± 9.8) µM and 13.5 (± 3.5) µM, respectively, in this assay. The N-methylated analogue 9 failed 50 to inhibit tubulin polymerization even at concentrations as high as 200 µM (data not shown). These results are consistent with the idea that compound 8a exerts some of its cytotoxic effects on cells through inhibition of tubulin polymerization. The less potent inhibition of tubulin polymerization by compounds 11d 55 and 11e is consistent with the general trend towards decreasing potency (but still significant), as determined from GI 50 values from the cancer cell screens, when compared to compound 8a, and is also consistent with the molecular docking studies. 85 However, based on the in vitro assay results, it would appear that the cytotoxic effects of compound 9 observed in cell culture are not mediated by inhibition of tubulin polymerization, but are instead the result of an unknown mechanism of action. 
Conclusions
We have evaluated a small library of novel 4-heteroaryl-5-aryl-(2H)-1,2,3-triazoles that are structurally related to transcyano CA-4 analogues that inhibit tubulin polymerization. 5 These compounds have been evaluated in a panel of 60 human cancer cell lines for their anti-cancer activities, and in assays to determine their ability to inhibit tubulin polymerization. The most potent compound, 8a, and two closely related analogues, 8b and 8g, were also tested for cytotoxicity against triple 10 negative Hs578T breast cancer cell lines. Compound 8a, a benzothiophen-2-yl derivative was shown to be a more potent anti-cancer agent than its isosteric indol-2-yl (8i) and benzofuran-2-yl (8g) congeners. Compound 8a was also found to be the most effective inhibitor of tubulin polymerization. 15 However, the benzothiophen-3-yl isostere of 8a, compound 11a, did not possess any significant anti-cancer activity, although indol-3-yl analogues that incorporate a 3,4,5-trimethoxyphenyl (11d) or a 3,5-dimethoxyphenyl (11e) moiety into their structure were potent anti-cancer agents. 20 Interestingly, a significant decrease in anti-cancer activity was observed with the N-2-methylated analogue 9 when compared to the parent compound 8a.
In summary, the anti-cancer screening data, inhibition of 25 tubulin polymerization, and molecular docking studies are all promising indicators that compound 8a warrants further study as a potential anti-cancer agent.
EXPERIMENTAL PROCEDURES
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General synthetic procedure for the synthesis of 4-heteroaryl-5-(substituted phenyl)-2H-1,2,3-triazoles (8a-i and 11a-e): 25 Sodium azide (0.01 mol) in DMSO (1 ml) was added to the appropriate heteroaryl cyanostilbene (0.01 mol) followed by 35 addition of L-proline (0.002 mol). The resulting reaction mixture was heated to 100 °C and stirred for 1-6 h. After completion of the reaction, the reaction mixture was cooled to 20 o C, water (10 ml) was added, and the resulting slurry was extracted with ethyl acetate (2x10 ml). The organic layers were 40 separated and combined, dried over anhydrous sodium sulphate, concentrated on a rotovaporator and purified by silica gel column chromatography (ethylacetate:hexanes 1:4) to afford the pure product. proportional to the number of viable cells. The fluorescence intensity of control (untreated) cells was taken as 100% viability, and the relative cell viability compared to control was calculated.
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Inhibition of tubulin polymerization assay: The tubulin polymerization was performed in 80 mM PIPES (pH 6.9) buffer containing 2 mM MgCl 2 , 0.5 mM EGTA, 100 mM GTP, and 10% (v/v) glycerol. The assay buffer was prepared on ice immediately prior to performing the tubulin polymerization 100 experiments in order to minimize GTP hydrolysis. Tubulin (4 mg) was reconstituted in 1 mL of cold assay buffer for a final concentration of 4 mg/mL. The reconstituted tubulin was placed on ice for a minimum of 3 minutes prior to starting the experiment. added to each well and polymerization was initiated by placing the plate at 37 °C. Polymerization was measured over time by monitoring the change in absorbance at 340 nm. The initial portion of the reaction was fit to a linear equation and the slope was used to estimate the rate of tubulin polymerization. The 115 rate of polymerization in the presence of triazole analogue was normalized against the control reaction and percent activity was plotted against the log of the inhibitor concentration. The IC 50 values for test compounds were calculated using a variable slope dose-response curve.
